CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Bayesian Interpretation of the EXCEL Trial and Other Randomized Clinical Trials of Left Main Coronary Artery Revascularization Comprehensive Investigation of Circulating Biomarkers and their Causal Role in Atherosclerosis-related Risk Factors and Clinical Events Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Feasibility and efficacy of the ultrashort side branch dedicated balloon in coronary bifurcation stenting Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: A national multicenter study The Science Underlying COVID-19: Implications for the Cardiovascular System Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
|<<... 127 128 129 130 131 132 133 ...>>|

Review Article2009 May 30;373(9678):1849-60.

JOURNAL：Lancet. Article Link

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Antithrombotic Trialists’ (ATT) Collaboration. Keywords: aspirin; cardiovascular events; primary prevention; diabetes mellitus

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top